Samik Pharmaceuticals announces 2026 value-up plan and continued high dividend

Samik Pharmaceuticals discloses 2026 value-up plan: aims to achieve mid- to long-term vision 'Re-Leap2030'
Targets 2030 revenue of KRW 130 billion and operating profit of KRW 11 billion, solidifying growth foundation in 2026
Qualified as high-dividend company: 2025 dividend payout ratio 25%, dividend amount KRW 368 million (up 28.6% YoY)
Shareholders receiving 2025 year-end dividend eligible for separate taxation benefit when filing 2026 comprehensive income tax
Key strategies: maximize CSO operational efficiency, strengthen market leadership with innovative drugs, expand CMO orders, advance long-acting injectable platform, diversify via subsidiary Pharmbay
This plan contains forward-looking information and may change due to future market conditions

Filing: Corporate Value Enhancement Plan (Voluntary Disclosure) (2026 Samik Pharmaceutical Co., Ltd. Corporate Value Enhancement Plan)
Company: Samik Pharm (014950)
Submission: Samik Pharm Co., Ltd.
Receipt: 05-06-2026
Under KRX KOSDAQ Market Division